OPRX OptimizeRx Corporation

ROCHESTER, MI and Cegedim Dendrite recently announced their plans to enter into an exclusive relationship to offer a Web-based savings and patient support program for leading prescription and healthcare brands. The partnership, which was announced at the DTC National Conference, brings together two leaders in an emerging industry segment that aims to help patients begin and maintain their therapies.

OPTIMIZERx has quickly established itself as the online leader for providing patients a central way to access and enroll in over 150 savings and support programs. Cegedim Dendrite, through its Opus Health division, was the first company to offer adjudicated patient support cards to the marketplace and now has more than 45 million money saving "loyalty" cards in circulation, which physicians and pharmacies typically distribute to patient.

The partnership will allow existing Cegedim Dendrite customers to integrate an optimized Web search tool into their marketing mix, while getting consistent messaging and reporting across all marketing channels.

Meanwhile, for healthcare brands without existing patient programs, the partnership supports the launch of, OPTIMIZERx's proprietary system, OFFERx(TM), a turnkey solution that integrates the development, promotion and management of customizable patient-offer programs.

"This is especially helpful for brands seeking to engage and enroll more qualified consumers into their patient programs, which can begin with the OFFERx platform and then expand to a complete relationship marketing program with Cegedim Dendrite," says Harvey Brofman, Vice President and General Manager of Cegedim Dendrite's OPUS Health division.

Under the partnership, OPUS Health will manage the loyalty cards generated through OFFERx. To help administer the program, OPUS Health will leverage its unique, contracted relationship with more than 61,000 pharmacies, which represents the largest pharmacy network in the industry.

"OFFERx now will allow more brands to take the next step in engaging and supporting their targeted patients," says David Harrell, CEO of OPTIMIZERx Corp. "Right now, only a small number of pharmaceutical brands have implemented a savings and patient support program as part of their marketing efforts."

Together, the two companies make OFFERx a complete, end-to-end system, beginning with direct marketing to consumers and physicians at the front end, and fulfillment, reporting and analysis at the back-end.

"Through our partnership with Cegedim Dendrite," Harrell says, "we can deliver powerful solutions to more brands seeking to expand product access, adherence and loyalty."

About Cegedim Dendrite

Cegedim Dendrite provides the pharmaceutical companies around the world with vital support for successful Customer Relationship Management (CRM) activities. With nearly 200,000 sales representatives using its products worldwide, Cegedim Dendrite is the world's leading CRM provider for the life sciences industry. This business unit, created in May 2007 when the France-based CEGEDIM S.A. Group acquired Dendrite International, also provides sales, marketing and regulatory compliance solutions in more than 80 countries. To learn more, please see our website: www.cegedimdendrite.com.

About Cegedim

Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, pharmaceutical companies, healthcare professionals and insurance companies.

The world leader in pharmaceutical CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs more than 8,000 people in 80 countries and generated revenue of EUR 753 million in 2007. To learn more, please visit our website: www.cegedim.com.

About OPTIMIZERx Corporation

Founded in 2007, this web-based consumer information and patient support website has grown to host 1 million unique visitors, while its permanent subscriber base continues to grow each month. The website has given rise to peripheral offerings and capabilities, most obviously the newly launched OFFERx offer management system, as well as sophisticated online behavioral re-targeting, database marketing, branding and traditional offer marketing on behalf of brand-name pharmaceuticals, OTC medications, medical devices, products and services that provide OPTIMIZERx visitors and subscribers the highest possible value and the best possible medical outcome for their specific condition.

'SAFE HARBOR'

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contacts: OPTIMIZERx Corporation Investor Relations First Capital Investors, Inc. Email Contact (321) 221-2910

OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024